No Data
No Data
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences GAAP EPS of -$0.30
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Maintains Target Price $2
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $7 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)
No Data